BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,858,120 | -79.1% | 1,109,904 | -79.2% | 0.02% | -81.5% |
| Q2 2023 | $37,543,715 | -9.4% | 5,332,914 | +7.3% | 0.13% | -11.6% |
| Q1 2023 | $41,431,761 | +139222.6% | 4,967,837 | +91.8% | 0.15% | +37.4% |
| Q4 2022 | $29,738 | -99.9% | 2,590,392 | -1.0% | 0.11% | -15.7% |
| Q3 2022 | $32,964,000 | -2.0% | 2,616,157 | -17.7% | 0.13% | +1.6% |
| Q2 2022 | $33,622,000 | +2818.6% | 3,177,871 | +4385.7% | 0.12% | +4066.7% |
| Q1 2022 | $1,152,000 | +529.5% | 70,844 | +435.2% | 0.00% | +200.0% |
| Q4 2021 | $183,000 | -81.0% | 13,236 | -80.3% | 0.00% | -66.7% |
| Q3 2021 | $965,000 | -91.9% | 67,127 | -91.1% | 0.00% | -92.7% |
| Q2 2021 | $11,937,000 | +2540.9% | 755,032 | +1597.9% | 0.04% | +1950.0% |
| Q1 2021 | $452,000 | -68.7% | 44,469 | -85.3% | 0.00% | -77.8% |
| Q2 2020 | $1,446,000 | +460.5% | 303,400 | +305.9% | 0.01% | +350.0% |
| Q4 2019 | $258,000 | – | 74,744 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 1,105,673 | $8,237,000 | 6.28% |
| Sarissa Capital Management LP | 8,175,000 | $60,903,000 | 6.22% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,980,870 | $22,207,000 | 2.78% |
| DG Capital Management, LLC | 1,075,732 | $8,014,000 | 1.70% |
| Ghost Tree Capital, LLC | 900,000 | $6,705,000 | 1.49% |
| Parkman Healthcare Partners LLC | 538,370 | $4,011,000 | 1.03% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,835,810 | $43,477,000 | 0.86% |
| Formidable Asset Management, LLC | 470,419 | $3,470,000 | 0.80% |
| KNOTT DAVID M | 219,461 | $1,635,000 | 0.74% |
| Altium Capital Management LP | 250,000 | $1,863,000 | 0.70% |